Reviewing personalized medicine approaches for patients with advanced EGFR-mutated non-small cell lung cancer
Jorge Nieva, M.D. from Criterium’s Academic Thoracic Oncology Medical Investigators Consortium (ATOMIC) and the USC Norris Comprehensive Cancer Center discusses personalized medicine in practice for patients with advanced EGFR-mutated non-small cell lung cancer (NSCLC).
Learn about personalized medicine approaches for NSCLC
Studying prognostic and predictive biomarkers to tailor therapies to individual patients
Kari Wisinski, M.D. from Criterium’s Academic Breast Cancer Consortium (ABRCC) and the University of Wisconsin discusses her research focus and what drives her to advance patient care.
Exploring the standard of care and promising therapies in stage III non-small cell lung cancer
Jared Weiss, M.D., from the UNC Lineberger Cancer Center and Criterium’s Academic Thoracic Oncology Medical Investigators Consortium (ATOMIC) discusses the standard of care for stage III non-small cell lung cancer (NSCLC) and new therapies that may help improve care for patients.
Learn more about new developments in stage III NSCLC treatment
Dr. Swami discusses the recent JAVELIN Bladder 100 trial
Because diabetes can often lead to additional health issues, such as obesity, researchers set out to discover whether the condition would complicate cancer treatment for patients with bladder cancer. Umang Swami, M.D. from Criterium’s Academic Urology Research Investigators Consortium (AURIC) and the University of Utah Huntsman Cancer Institute comments on the recent JAVELIN Bladder 100 trial.
Reviewing the safety profile of a combination treatment for patients with gastric, esophageal or gastroesophageal junction adenocarcinoma
In an informative video, Samuel J. Klempner, M.D. from Criterium’s Academic GI Cancer Consortium (AGICC) and Massachusetts General Hospital, reviews the safety profile of givastomig plus nivolumab (Opdivo) and mFOLFOX6 (leucovorin, fluorouracil [5-FU], and oxaliplatin), a treatment for patients with HER2-negative, Claudin 18.2 (CLDN18.2)–positive gastric, esophageal, or gastroesophageal junction adenocarcinoma.